Pharma is leading the way in R&D investment in the UK, with cannabis medicine specialist GW splurging almost 1,345% of its total revenue on research according to an analysis.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh